XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher [Yahoo! Finance]
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $13.00 to $11.00. They now have an "outperform" rating on the stock.
Viracta Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]
Viracta Therapeutics Announces New Employment Inducement Grants
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer [Yahoo! Finance]